M&A
Merck Expands Oncology Pipeline With ArQule
Published: December 9th, 2019
The biopharmaceutical giant is paying a 107% premium for the target, which focuses on therapies for treating cancer and rare diseases.
Insights & Analysis
Industry insights that are curated and delivered to inform your dealmaking strategies. We select the most relevant information, providing a consistent, convenient source for exclusive intelligence and analysis.
Page 35
M&A
Drinks With The Deal: Chris Varelas
By David Marcus
|
Published: December 6th, 2019
The former Citi tech investment banker and author of 'How Money Became Dangerous' talks with The Deal’s David Marcus about working at Disneyland in the 1980s, being a tech banker after the dot-com crash and investing in influencers.
M&A
Thoma Bravo Takes Instructure Private Following Review
By Steve Gelsi
|
Published: December 4th, 2019
The $2 billion bid comes after the company announced a strategic review in October and after The Deal named the information tech company a target in January.
M&A
Discipline Crucial in 2020
By Alexandra Garfinkle
|
Published: December 2nd, 2019
M&A valuations remain frothy and Ebitda adjustments are growing, panelists cautioned at The 2019 Deal Economy Conference.
Activism
Vitamin Shoppe to Emphasize Organic Growth
By Alexandra Garfinkle
|
Published: December 2nd, 2019
Vitamin Shoppe GC David Kastin said that the company will pursue organic growth, while its soon-to-be parent pursues M&A.
Activism
Activists Find New Routes to M&A Opportunities
By Ronald Orol
|
Published: December 2nd, 2019
Insurgent managers are targeting larger companies and are taking on different roles, a panel of experts told The Deal Economy's 2019 conference.
Activism
M&A, Politics, SEC Top of Mind for Activists
By Ronald Orol
|
Published: December 2nd, 2019
Schulte Roth partner Aneliya Crawford discusses activism at large-cap companies, BMY-Celgene and insurgent prospects in a second Trump or Warren administration at The Deal Economy conference.
M&A
Pfizer Leans Toward Tuck-In Deals
By Armie Margaret Lee
|
Published: November 27th, 2019
This year, Pfizer’s first under the leadership of Albert Bourla, the biopharma company has done deals including the purchase of Array BioPharma and Therachon.
Activism
Lawyers Debate Icahn-Oxy Feud
By Greg Morcroft
|
Published: November 27th, 2019
Sidley's Kai Liekefett and Schulte's Ele Klein diverge in their opinions about Carl Icahn’s unyielding agitation at Occidental Petroleum.
